Novartis, a New Jersey drug manufacturer, filed the lawsuit in federal court in Portland over the program that allows hospitals and community health centers to get some medications at discount prices.

Novartis Pharmaceuticals filed a lawsuit against the State of Rhode Island seeking to block the enforcement of a new state ...

Given GLP-1 receptor agonists' established effects on weight, Poizeau and colleagues investigated whether the blockbuster ...

Schuyler County is to receive a settlement from a New Jersey pharmaceutical company and its affiliates after the county argued it contributed to the ongoing opioid ...

Ianalumab added to eltrombopag significantly prolonged the time to treatment failure (TTF) in adults with primary immune thrombocytopenia (ITP), a B cell-driven autoimmune disease, according to phase ...

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

Novartis's Ianalumab Meets Goals in Phase 3 Trials to Treat Primary Immune Thrombocytopenia Novartis said its ianalumab drug combined with eltrombopag met the primary endpoint in a late-stage trial, ...

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated ...

The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

Roche (RHHBY) and Novartis (NVS) are scheduled to meet with Swiss officials this week amid U.S. tariff threats on pharma ...